TWI800827B - 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌 - Google Patents

使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌 Download PDF

Info

Publication number
TWI800827B
TWI800827B TW110116831A TW110116831A TWI800827B TW I800827 B TWI800827 B TW I800827B TW 110116831 A TW110116831 A TW 110116831A TW 110116831 A TW110116831 A TW 110116831A TW I800827 B TWI800827 B TW I800827B
Authority
TW
Taiwan
Prior art keywords
patient
gdc
combination therapy
palbociclib
patients
Prior art date
Application number
TW110116831A
Other languages
English (en)
Chinese (zh)
Other versions
TW202203913A (zh
Inventor
珍妮佛 奧哈拉 勞赫勒
珊卓拉 米蘭
梅蘭妮 卡蘿 史密特
瑪裘瑞 Ｃ 格林
Original Assignee
美商建南德克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建南德克公司 filed Critical 美商建南德克公司
Publication of TW202203913A publication Critical patent/TW202203913A/zh
Application granted granted Critical
Publication of TWI800827B publication Critical patent/TWI800827B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW110116831A 2020-05-12 2021-05-10 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌 TWI800827B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023501P 2020-05-12 2020-05-12
US63/023,501 2020-05-12

Publications (2)

Publication Number Publication Date
TW202203913A TW202203913A (zh) 2022-02-01
TWI800827B true TWI800827B (zh) 2023-05-01

Family

ID=76250442

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110116831A TWI800827B (zh) 2020-05-12 2021-05-10 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌

Country Status (11)

Country Link
US (2) US11918561B2 (https=)
EP (1) EP4149476A1 (https=)
JP (3) JP2023500558A (https=)
KR (1) KR20230009390A (https=)
CN (2) CN115551513B (https=)
AU (1) AU2021272100B2 (https=)
CA (1) CA3182018A1 (https=)
IL (1) IL298071A (https=)
MX (1) MX2022014133A (https=)
TW (1) TWI800827B (https=)
WO (1) WO2021231250A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023009374A (es) * 2021-02-16 2023-08-16 Genentech Inc Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib.
IL315153A (en) * 2022-03-14 2024-10-01 Genentech Inc Combined treatments for breast cancer
CN121337802B (zh) * 2025-10-23 2026-04-14 安徽益普克医药科技发展有限公司 一种雌激素降解剂衍生物及其制备方法与用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310754A (zh) * 2016-03-15 2019-02-05 梅里麦克制药股份有限公司 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102529049B1 (ko) * 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
KR102358935B1 (ko) * 2014-02-12 2022-02-04 가부시키가이샤 한도오따이 에네루기 켄큐쇼 전자 기기
KR102785474B1 (ko) * 2014-12-18 2025-03-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
JP7019422B2 (ja) * 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
LT3810283T (lt) * 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
JP7826068B2 (ja) * 2022-03-11 2026-03-09 本田技研工業株式会社 パワーユニット、及びパワーユニットを搭載した作業機

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310754A (zh) * 2016-03-15 2019-02-05 梅里麦克制药股份有限公司 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法

Also Published As

Publication number Publication date
WO2021231250A1 (en) 2021-11-18
US20240173306A1 (en) 2024-05-30
CN115551513B (zh) 2025-05-02
CN115551513A (zh) 2022-12-30
JP2024102045A (ja) 2024-07-30
AU2024202832A1 (en) 2024-05-23
IL298071A (en) 2023-01-01
JP2023175688A (ja) 2023-12-12
CA3182018A1 (en) 2021-11-18
TW202203913A (zh) 2022-02-01
US11918561B2 (en) 2024-03-05
EP4149476A1 (en) 2023-03-22
AU2021272100A1 (en) 2022-11-17
CN120324434A (zh) 2025-07-18
MX2022014133A (es) 2022-11-30
KR20230009390A (ko) 2023-01-17
AU2021272100B2 (en) 2024-09-12
US12303495B2 (en) 2025-05-20
US20210353601A1 (en) 2021-11-18
JP2023500558A (ja) 2023-01-10

Similar Documents

Publication Publication Date Title
JP7667132B2 (ja) Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
US12303495B2 (en) Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
US20260041695A1 (en) Combination therapies for treatment of breast cancer
TWI808648B (zh) 使用包含gdc-9545及gdc-0077之組合療法治療乳癌
TWI881203B (zh) 使用包含gdc-9545及帕他色替之組合療法治療乳癌
AU2024202832B2 (en) Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
HK40129153A (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
HK40084792B (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
TWI828060B (zh) 使用包含gdc-9545及阿貝西尼或瑞博西尼之組合療法治療乳癌
HK40084792A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
HK40101173A (zh) 使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌
HK40066922A (zh) 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌
HK40098151A (zh) 使用包括gdc-9545以及阿贝西利或者瑞博西尼的组合疗法治疗乳腺癌
HK40101825A (zh) 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌